Where to Buy Peptides in 2026: The Complete Guide
Grey-market vendors are disappearing. Compounding pharmacies are waiting. Telehealth is arriving. Here's every pathway.
The peptide market is in the middle of the most significant regulatory shift in years. On April 15, 2026 the FDA removed 12 peptides from Category 2 (the “do not compound” list) — but that is not the same as making them compoundable; none have yet been added to the 503A list, which requires PCAC review (July 23–24, 2026) and FDA rulemaking. The SAFE Drugs Act threatens the grey-market model. Major vendors have shut down. This guide is updated as the regulatory picture evolves.
The Three Pathways to Peptides in 2026
The peptide market is splitting into three distinct channels, each with different tradeoffs on access, cost, quality, and legal risk.
Pathway 1: Grey-Market Research Chemical Vendors
What it is: Websites selling peptides labeled “for research use only” directly to consumers without a prescription.
The reality: This has been the dominant pathway for years. It’s the most accessible and typically the cheapest option. It’s also under sustained and increasing legal pressure.
What’s changed in 2026:
- Peptide Sciences (largest vendor, B+ rated) shut down March 6
- Amino Asylum (popular budget vendor) was raided by FDA in June 2025
- 8+ vendors have closed since 2025
- FDA warning letters issued to Prime Peptides, SwissChems, Xcel Peptides, Summit Research
- ITC exclusion orders block tirzepatide imports entirely
- SAFE Drugs Act (H.R. 6509) would make the RUO model explicitly illegal
Who’s still operating (with PeptideExaminer grades):
| Vendor | Grade | Finnrick Data | Key Strength | Key Concern |
|---|---|---|---|---|
| Eternal Peptides | B | BPC-157 A, Semaglutide B, Tirzepatide B | Broadest Finnrick testing | Newer vendor, limited history |
| Paradigm Peptides | C+ | Retatrutide A (only product tested) | Decade of operations, BBB A+ | No public COAs, 2024 shutdown |
| Prime Peptides | C- | None | COAs available, responsive service | FDA warning letter Dec 2024 |
| Strate Labs | D+ | None | Long operating history | ITC Cease and Desist Order |
For the full assessment of each vendor, see our Vendor Ratings.
Cost: Typically $40-80 per 5mg vial for common peptides. No physician visit required. No prescription needed.
Legal risk: Increasing. The “research use only” defense has been rejected by courts (All American Peptide forfeiture, Tailor Made Compounding conviction). The SAFE Drugs Act would codify this rejection.
Pathway 2: Compounding Pharmacies (Not Yet Available for Most Peptides)
What it is: Licensed 503A or 503B pharmacies preparing peptides with pharmaceutical-grade ingredients under a physician’s prescription.
Current status: Compounding of most popular peptides is still prohibited. On April 15, 2026 the FDA removed 12 peptides — including BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, and DSIP — from Category 2, but removal from the “do not compound” list does not make them compoundable; none are yet on the 503A list. Others popular in this space — CJC-1295, ipamorelin, AOD-9604, Thymosin Alpha-1 — were NOT part of that action and remain Category 2 (they are on a separate legal track).
What you need:
- A physician willing to prescribe the peptide (not all physicians are familiar with peptide therapy)
- A licensed compounding pharmacy with USP 795/797 compliance
- A valid prescription specifying the peptide, dose, route, and quantity
Currently compoundable (Category 1): Sermorelin, GHK-Cu (topical only), VIP, NAD+. These are available through compounding pharmacies right now without waiting for any reclassification.
Removed from Category 2 on April 15, 2026 (not yet compoundable — awaiting PCAC review + rulemaking): BPC-157, TB-500, KPV, MOTS-c, Emideltide/DSIP, Semax, Epitalon, LL-37, GHK-Cu (injectable), Melanotan II, PEG-MGF, Dihexa. PCAC reviews seven of these on July 23–24, 2026 (BPC-157, KPV, TB-500, MOTS-c on the 23rd; DSIP, Semax, Epitalon on the 24th); the other five go to a later meeting before the end of February 2027.
Still Category 2 (separate legal track, not part of the April action): Thymosin Alpha-1, CJC-1295, Ipamorelin, AOD-9604, Selank, Kisspeptin-10. GHRP-2 and MK-677 also remain outside the reclassification (PCAC voted against MK-677 in December 2024).
Cost: Typically $150-400/month depending on peptide and dose, plus physician consultation ($100-250). More expensive than grey-market but includes quality controls, physician oversight, and legal protection.
Quality advantage: Pharmaceutical-grade APIs, sterility testing, endotoxin testing, batch consistency, and regulatory accountability. This is the pathway regulators are trying to create as an alternative to the grey market.
Pathway 3: Telehealth Platforms
What it is: Online medical platforms offering physician consultation, prescription, and delivery of peptide therapies — similar to how Hims & Hers operates for other medications.
Who’s entering:
Hims & Hers (Grade: B+) — NYSE-listed, 2.5M+ subscribers, confirmed peptide product line in development with California manufacturing facility. Not yet launched but the most credible entrant.
Ro, Noom, and other telehealth platforms — Various stages of evaluating or developing peptide offerings.
Smaller peptide-focused telehealth — Multiple startups offering physician-supervised peptide protocols. Quality and legitimacy vary significantly. Research any platform before sharing payment information.
Cost: Expected to be between compounding pharmacy pricing and grey-market pricing. The telehealth model adds convenience (no pharmacy visit, direct-to-door delivery) but also adds consultation fees and platform margins.
Timeline: Hims & Hers hasn’t announced a launch date for their peptide line. Other platforms are similarly in development. This pathway is coming but isn’t fully available yet.
Pathway Comparison
| Factor | Grey Market | Compounding Pharmacy | Telehealth |
|---|---|---|---|
| Availability | Now (shrinking) | Not yet — removal from Cat 2 ≠ compoundable; awaiting 503A listing | Coming soon |
| Prescription needed | No | Yes | Yes |
| Cost per month | $40-150 | $150-400 | $100-300 (est.) |
| Quality controls | Vendor-dependent | Regulated (USP 795/797) | Platform-dependent |
| Legal risk | High and increasing | None (only once actually added to the 503A list) | None |
| Physician oversight | None | Required | Built-in |
| Adverse event monitoring | None | Required | Platform-dependent |
What About FDA-Approved Peptides?
Some popular peptide targets have FDA-approved pharmaceutical versions:
Semaglutide (GLP-1): Available as Ozempic, Wegovy, and Rybelsus through standard prescriptions. Oral Wegovy at $149/month is now available. No reason to use grey-market semaglutide when legal, quality-controlled versions exist.
Tirzepatide (GLP-1/GIP): Available as Mounjaro and Zepbound through standard prescriptions. Protected by Lilly’s ITC exclusion orders — grey-market tirzepatide carries the highest legal risk in the market.
Bremelanotide / PT-141: Available as Vyleesi for hypoactive sexual desire disorder. FDA-approved, prescription-only.
Sermorelin: Category 1 — currently compoundable through licensed pharmacies with a prescription. The only legal GH secretagogue option right now.
For these compounds, the legal pharmaceutical pathway is available, quality-controlled, and safer. The grey-market alternative makes sense only on price — and the risk calculus has shifted against that argument.
The Decision Framework
Here’s how to think about which pathway fits your situation:
If the peptide you want has an FDA-approved version (semaglutide, tirzepatide, PT-141): Use the approved version. Full stop. The quality, safety, and legal advantages are overwhelming.
If you can wait for the compounding pathway and want the safest option: Find a physician who prescribes peptide therapy now. Establish the relationship. When these peptides are actually added to the 503A compoundable list (after PCAC review and FDA rulemaking — not merely removed from Category 2, which has already happened), you’ll be ready to get a prescription filled at a compounding pharmacy. This is the pathway with the best long-term risk profile.
If you want peptides now and accept grey-market risk: Use vendors with independent Finnrick testing data. Verify batch-specific COAs. Use the lowest effective dose from published research. Have a plan for adverse events. Understand that the vendor may not exist next month.
If you’re new to peptides: Start with our peptide profiles to understand what the evidence actually shows. Then talk to a physician. The “research” label is legally meaningless and the evidence gaps are real regardless of how you source the product.
This guide will be updated when the FDA publishes formal reclassification. Bookmark this page.
PeptideExaminer — We don’t sell peptides. We tell you the truth about them.